ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Adverse events"

  • Abstract Number: 1542 • 2018 ACR/ARHP Annual Meeting

    Real-World Data from a Post-Approval Safety Surveillance Study of Tofacitinib Vs Biologic Dmards and Conventional Synthetic Dmards: Five-Year Results from a US-Based Rheumatoid Arthritis Registry

    Joel Kremer1, Laura C. Cappelli2, Carol J. Etzel3, Jeffrey Greenberg3, Jamie Geier4, Ann Madsen4, Connie Chen4, Alina Onofrei3, Christine J Barr3, Dimitrios A. Pappas3, Kimberly J Dandreo3, Andrea Shapiro5, Carol A Connell6 and Arthur Kavanaugh7, 1Albany Medical College and the Center for Rheumatology, Albany, NY, 2Johns Hopkins University, Baltimore, MD, 3Corrona LLC, Waltham, MA, 4Pfizer Inc, New York, NY, 5Pfizer Inc, Peapack, NJ, 6Pfizer Inc, Groton, CT, 7University of California, San Diego School of Medicine, La Jolla, San Diego, CA

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A prospective observational 5-year study, embedded within the US Corrona RA registry,…
  • Abstract Number: 2723 • 2018 ACR/ARHP Annual Meeting

    Patient Experience in ANCA-Associated Vasculitis Evolves over Time from Diagnosis and Both Benefits and Adverse Impacts Are Felt with Current Therapy

    Peter Rutherford1, Dieter Goette1, James O`Donoghue2 and Xierong Liu2, 1Medical Affairs, Vifor Pharma, Zurich, Switzerland, 2Elma Research, London, United Kingdom

    Background/Purpose: ANCA-associated vasculitis (AAV) leads to both acute illness and a long-term condition in which the disease remits and relapses. Therapy is often complex and…
  • Abstract Number: 346 • 2018 ACR/ARHP Annual Meeting

    Immune-Related Adverse Events: Development of a Pilot Immune-Related Adverse Events Clinic for Expedited and Effective Patient Care

    Pankti Reid1 and Reem Jan2, 1Internal Medicine, rheumatology, University of Chicago, Chicago, IL, 2Medicine, Rheumatology, University of Chicago, Chicago, IL

    Background/Purpose: The growing use of cancer immunotherapy and checkpoint inhibitors has led to a steep rise in immune-related adverse events (irAEs). Despite expanding research efforts,…
  • Abstract Number: 1612 • 2018 ACR/ARHP Annual Meeting

    Myocardial Infarctions Among Ankylosing Spondylitis Patients in a Large US Insurance Database

    Maureen Dubreuil1, Christine Peloquin2, David T. Felson3 and Tuhina Neogi3, 1Clinical Epidemiology and Rheumatology, Boston University School of Medicine, Boston, MA, 2Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 3Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA

    Background/Purpose: Risk of myocardial infarction (MI) is estimated to be increased up to 60% in ankylosing spondylitis (AS).  Studies in patients with rheumatoid arthritis, psoriatic…
  • Abstract Number: 2724 • 2018 ACR/ARHP Annual Meeting

    Variable Response to Induction Therapy and Significant Burden of Treatment Adverse Events over the First 12 Months in Incident ANCA-Associated Vasculitis (AAV) Patients – a Study of Routine Clinical Practice in the EU

    Peter Rutherford1, Dieter Goette1, Melinda Stamm2 and Xierong Liu2, 1Medical Affairs, Vifor Pharma, Zurich, Switzerland, 2Elma Research, London, United Kingdom

    Background/Purpose: Aims of therapy in incident AAV patients include ensuring rapid diagnosis, assessment of comorbidity, disease activity, and vasculitis damage before commencing treatment with a…
  • Abstract Number: 350 • 2018 ACR/ARHP Annual Meeting

    Clinical Correlates of Immune-Related Adverse Events for Patients with Melanoma Treated with Checkpoint Inhibitors and a Noted Significant Difference in Peripheral Lymphocyte Counts

    Pankti Reid1, Tara Chongsuwat2, Anisha Dua3 and Jason Luke4, 1Internal Medicine, rheumatology, University of Chicago, Chicago, IL, 2Oncology Research Coordinator, University of Chicago, Chicago, IL, 3Medicine, University of Chicago, Chicago, IL, 4Hematology Oncology, University of Chicago, Chicago, IL

    Background/Purpose: Checkpoint immunotherapy has become the standard of care in treating advanced melanoma. These medications have been associated with immune-related adverse events (irAEs). Accurate methods…
  • Abstract Number: 1768 • 2018 ACR/ARHP Annual Meeting

    Kidney Involvement, Poor Performance Status, and Higher Cumulative Dose of Glucocorticoid Are the Risk Factors of the Discontinuation of Immunosuppressant in Patients with Antineutrophil Cytoplasmic Antibody Associated Vasculitis

    Takamasa Murosaki, Takeo Sato, Katsuya Nagatani and Seiji Minota, Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan

    Background/Purpose: The use of immunosuppressant (IS) with glucocorticoid is recommended as remission induction treatment for severe cases with antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV).…
  • Abstract Number: 2739 • 2018 ACR/ARHP Annual Meeting

    Systemic Vasculitis: Incidence of Glucocorticoid Related Adverse Events

    Luciano Fernando Lo Giudice1, Marina Scolnik2, Jose Maximiliano Martinez P3, Aurelia Luissi1, Valeria Scaglioni2 and Enrique R Soriano2, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, 2Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, 3Rheumatology, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: The glucocorticoid toxicity index (GTI) (Miloslavsky et al. Ann Rheum Dis 2017) is useful to assess impact on morbility associated with these drugs. It…
  • Abstract Number: 353 • 2018 ACR/ARHP Annual Meeting

    Immune-Related Adverse Events Associated with Immunotherapy in Solid Organ Tumors. Study of 102 Cases from a Referral Single Center for Last 3 Years

    José Luis Martín-Varillas1, Íñigo González-Mazón1, Belén Atienza-Mateo1, Marina Delagado Ruiz2, Isabel Bernat Piña2, Diana Prieto Peña3, Monica Calderón Goercke3, Lara Sánchez-Bilbao1, Eva Peña Sainz-Pardo2, Almudena García Castaño2, Miguel Angel González-Gay2 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain

    Background/Purpose: Immune checkpoint blockade therapy (ICTB) has shown remarkable benefit in different cancer types. Blockade of intrinsic down-regulators of immunity increases the activity of the…
  • Abstract Number: 1916 • 2018 ACR/ARHP Annual Meeting

    Neutrophil-to-Lymphocyte Ratio Prospectively Predicts the Development of Rheumatic Immune-Related Adverse Events from PD-1 Inhibitor Therapy

    Christopher McMaster1,2, David Liew3,4, Pallavi Shamdasani5, Jessica Leung3,4, Albert Frauman6,7, Jonathan Cebon7,8 and Russell Buchanan4,9, 1Department of Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg, Australia, 2Health and Biomedical Informatics Centre, University of Melbourne, Parkville, Australia, 3Medicine, University of Melbourne, Parkville VIC, Australia, 4Rheumatology, Austin Health, Heidelberg VIC, Australia, 5Department of Rheumatology, Austin Health, Heidelberg, Australia, 6Department of Clinical Pharmacology and Therapeutics, Austin Health, Melbourne, Australia, 7Medicine, University of Melbourne, Melbourne, Australia, 8Olivia Newton-John Cancer Wellness & Research Centre, Melbourne, Australia, 9Medicine, University of Melbourne, Parkville, Australia

    Background/Purpose: Rheumatic immune-related adverse events (irAEs) from PD-1 inhibitor immune checkpoint immunotherapy can not only lead to cessation of immunotherapy, but also can be disabling…
  • Abstract Number: 2744 • 2018 ACR/ARHP Annual Meeting

    Giant-Cell Arteritis: Is Glucocorticoid-Sparing Treatment Still Relevant? a Retrospective Study

    Segolene Perrineau1, Romain Paule2, Pierre Charles3, Martine GAYRAUD4, Benjamin Terrier1,5, Loïc Guillevin1, Luc Mouthon1,5 and Alexis Régent2,5, 1Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris Descartes, PARIS, France, 2Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris Descartes, Paris, France, 3Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France, 4Department of Internal Medicine, Institut Mutualiste Montsouris, PARIS, France, 5Institut Cochin, INSERM U1016, CNRS UMR 8104, PARIS, France

    Background/Purpose: Giant-cell arteritis (GCA) is the most common primary large-vessel vasculitis affecting patients over 50 yr. Despite frequent and severe adverse events (AEs), glucocorticoids (GCs)…
  • Abstract Number: 448 • 2018 ACR/ARHP Annual Meeting

    Tizanidine, a Frequently Used Muscle Relaxant, Is Associated with Severe Hypotension: Role of Cytochrome P450 1A2 Inhibition in Routine Clinical Practice

    Sandip Chaugai1, Alyson Dickson2, Megan Shuey2, QiPing Feng2, Katherine Barker2, James Luther2, C. Michael Stein3 and Cecilia P. Chung3, 1Medicine, Vanderbilt University Medical Center, Nashville, TN, 2Vanderbilt University Medical Center, Nashville, TN, 3Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Tizanidine, a muscle relaxant widely used for musculoskeletal pain, can lower blood pressure and is metabolized by the cytochrome P450 1A2 (CYP1A2). As a…
  • Abstract Number: 1919 • 2018 ACR/ARHP Annual Meeting

    Individual Short-Acting Opioids and the Risk of Opioid-Related Adverse Events in Adolescents

    Cecilia P. Chung1, S. Todd Callahan2, William Cooper2, William Dupont3, Katherine Murray1, Andrew Franklin4, Kathi Hall5, Judith A. Dudley5, C. Michael Stein1 and Wayne Ray5, 1Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, 2Pediatrics, Vanderbilt University Medical Center, Nashville, TN, 3Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 4Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, 5Health Policy, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Hydrocodone, codeine, oxycodone, and tramadol are frequently prescribed for moderate pain in adolescents. However, pharmacokinetic and pharmacodynamic differences between these short-acting opioids could affect…
  • Abstract Number: 2783 • 2018 ACR/ARHP Annual Meeting

    EULAR Task Force Recommendations for a Minimum Core Set of Parameters to be Collected in Giant Cell Arteritis Registries and Databases

    Lisa Ehlers1, Johan Askling2, Johannes W. J. Bijlsma3, Maria C. Cid4, Maurizio Cutolo5, Bhaskar Dasgupta6, Christian Dejaco7,8, William G Dixon9, Nils Feltelius10,11, Axel Finckh12, Kate Gilbert13, Sarah Mackie14, Alfred Mahr15, Eric L. Matteson16, Lorna Neill17, Carlo Salvarani18,19, Wolfgang A. Schmidt20, Anja Strangfeld21, Ronald van Vollenhoven22 and Frank Buttgereit1, 1Department of Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Berlin, Germany, 2Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 3Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 4University of Barcelona, Barcelona, Spain, 5Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, 6Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, 7Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, 8Rheumatology, Hospital of Bruneck, Bruneck, Italy, 9Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 10Medical Products Agency, Uppsala, Sweden, 11Cross-Committee Task Force on Registries at the European Medicines Agency, London, United Kingdom, 12University Hospital of Geneva, Geneva, Switzerland, 13Patient Representative from PMRGCAuk, London, United Kingdom, 14NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom, 15Internal Medicine, Saint-Louis Hospital, Paris Diderot University, Paris, France, 16Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, 17Patient Representative from PMR-GCA Scotland, Perth, United Kingdom, 18Università di Modena e Reggio Emilia, Modena, Italy, 19Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy, 20Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, 21Epidemiology, German Rheumatism Research Center, Berlin, Germany, 22Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands

    Background/Purpose: Giant cell arteritis (GCA) represents the most common form of primary systemic vasculitis, and is frequently associated with comorbidities related either to the disease…
  • Abstract Number: 552 • 2018 ACR/ARHP Annual Meeting

    Drug Tolerability and Discontinuation Reasons of 7 Biologics in 4466 Treatment Courses of Rheumatoid Arthritis -the Answer Cohort Study-

    Kosuke Ebina1, Makoto Hirao2, Motomu Hashimoto3, Wataru Yamamoto4, Akira Onishi5, Toru Hirano6, Ryota Hara7, Masaki Katayama8, Shuzo Yoshida9, Koji Nagai9, Yonsu Son10, Hideki Amuro10, Kengo Akashi11, Koichi Murata3, Kosaku Murakami12, Keiichi Yamamoto13 and Hideki Yoshikawa14, 1Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, 2Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, 3Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Department of Health Information Management, Kurashiki Sweet Hospital, Okayama, Japan, 5Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 6Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan, 7The Center for Rheumatic Diseases, Department of Orthopaedic Surgery, Nara Medical University, Kashihara, Japan, 8Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan, 9Department of Internal Medicine (IV), Osaka Medical College, Osaka, Japan, 10First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, 11Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 12Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 13Department of Medical Statistics, Osaka City University, Osaka, Japan, 14Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Suita Osaka, Japan

    Background/Purpose: Drug tolerability indicates both the patient’s and doctor’s satisfaction and useful summary measure of overall treatment effectiveness and toxicity. Although more than 5 years…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology